# Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer

> **NCT00493857** · PHASE2 · TERMINATED · sponsor: **YM BioSciences** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Nimotuzumab Humanized Monoclonal Antibody
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT00493857
- **Lead sponsor:** YM BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-12
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** Cohort 2 not going forward. Manadate changes in Company
- **Last updated:** 2008-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493857, "Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00493857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*